pembrolizumab

You have access
Pembrolizumab-induced Remission After Failure of Axicabtagene Ciloleucel: Case Report and Literature Review
MARIA DIMOU, AIKATERINI BITSANI, WOLFGANG BETHGE, PANAYIOTIS PANAYIOTIDIS and THEODOROS P. VASSILAKOPOULOS

In Vivo November 2021, 35 (6) 3401-3406; DOI: https://doi.org/10.21873/invivo.12639
You have access
Impact of C-reactive Protein Flare Response in Patients With Advanced Urothelial Carcinoma Who Received Pembrolizumab
IKKO TOMISAKI, MIRII HARADA, KEI TOKUTSU, AKINORI MINATO, YUJIRO NAGATA, RIEKO KIMURO, MASAHIRO MATSUMOTO and NAOHIRO FUJIMOTO

In Vivo November 2021, 35 (6) 3563-3568; DOI: https://doi.org/10.21873/invivo.12659
You have access
Clinical Outcomes of Mixed Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy
NOBUKI FURUBAYASHI, TAKAHITO NEGISHI, NAOTAKA SAKAMOTO, SHINGO TAMURA, FUTOSHI MOROKUMA, YOOHYUN SONG, YOSHIFUMI HORI, TOSHIHISA TOMODA, NARIHITO SEKI, KENTARO KUROIWA and MOTONOBU NAKAMURA

In Vivo September 2021, 35 (5) 2869-2874; DOI: https://doi.org/10.21873/invivo.12575
You have access
Case Series of Pleomorphic Carcinoma of the Lung Treated With Immune Checkpoint Inhibitors
KANA HAYASHI, KOTARO TOKUI, MINEHIKO INOMATA, KENJI AZECHI, ISAMI MIZUSHIMA, NAOKI TAKATA, CHIHIRO TAKA, SEISUKE OKAZAWA, KENTA KAMBARA, SHINGO IMANISHI, TOSHIRO MIWA, RYUJI HAYASHI, SHOKO MATSUI, SATOSHI NOMURA and KAZUYUKI TOBE

In Vivo May 2021, 35 (3) 1687-1692; DOI: https://doi.org/10.21873/invivo.12428
You have access
Pembrolizumab Versus Combined Chemotherapy With Gemcitabine and Paclitaxel: A Comparative Assessment of Clinical Outcomes in Patients With Platinum-refractory Advanced Urothelial Cancer
AYANA TAKEMURA, YUTO MATSUSHITA, KEITA TAMURA, TAKAYUKI SUGIYAMA, MASAO NAGATA, ATSUSHI OTSUKA and HIDEAKI MIYAKE

In Vivo May 2021, 35 (3) 1889-1894; DOI: https://doi.org/10.21873/invivo.12453
You have access
Prognosis of Immune-related Adverse Events in Patients With Advanced Gastric Cancer Treated With Nivolumab or Pembrolizumab: A Multicenter Retrospective Analysis
TAKAYUKI ANDO, AKIRA UEDA, KOHEI OGAWA, IORI MOTOO, SHINYA KAJIURA, TAKAHIKO NAKAJIMA, KATSUHISA HIRANO, TOMOYUKI OKUMURA, KENICHIRO TSUKADA, TAKUO HARA, NOBUHIRO SUZUKI, NAOKATSU NAKADA, NAOKI HORIKAWA, TSUTOMU FUJII and ICHIRO YASUDA

In Vivo January 2021, 35 (1) 475-482; DOI: https://doi.org/10.21873/invivo.12281
You have access
Association Between the Efficacy of Pembrolizumab and Low STK11/LKB1 Expression in High-PD-L1-expressing Non-small-cell Lung Cancer
TSUKASA HASEGAWA, NORIKO YANAGITANI, HIRONORI NINOMIYA, HIROAKI SAKAMOTO, TAKEHIRO TOZUKA, HIROSHI YOSHIDA, YOSHIAKI AMINO, SHINYA UEMATSU, TAKAHIRO YOSHIZAWA, RYO ARIYASU, KEN UCHIBORI, SATORU KITAZONO, ATSUSHI HORIIKE and MAKOTO NISHIO

In Vivo September 2020, 34 (5) 2997-3003; DOI: https://doi.org/10.21873/invivo.12131
You have access
Combination of Pembrolizumab With Platinum-containing Chemotherapy for Pleomorphic Carcinoma of the Lung
SHINICHIRO OKAUCHI, YUIKA SASATANI, TOSHIHIRO SHIOZAWA, HIDEYASU YAMADA, KUNIHIKO MIYAZAKI, NORIO TAKAYASHIKI and HIROAKI SATOH

In Vivo May 2020, 34 (3) 1439-1443; DOI: https://doi.org/10.21873/invivo.11926
You have access
Severe Thrombocytopenia Associated With Pembrolizumab in Patients With Non-small Cell Lung Cancer (NSCLC): A Case Report and Literature Review
ATSUTO MOURI, KYOICHI KAIRA, AYAKO SHIONO, YU MIURA and HIROSHI KAGAMU

In Vivo March 2020, 34 (2) 877-880; DOI: https://doi.org/10.21873/invivo.11852

Main menu

User menu

Search

pembrolizumab

Pages